This article is available to subscribers. Subscribe now. Already have an account? Sign in

Original ArticleFree PreviewArchive

Ten-Year Results of a Randomized Clinical Trial Comparing Radical Mastectomy and Total Mastectomy with or without Radiation

List of authors.
  • Bernard Fisher, M.D.,
  • Carol Redmond, Sc.D.,
  • Edwin R. Fisher, M.D.,
  • Madeline Bauer, Ph.D.,
  • Norman Wolmark, M.D.,
  • D. Lawrence Wickerham, M.D.,
  • Melvin Deutsch, M.D.,
  • Eleanor Montague, M.D.,
  • Richard Margolese, M.D.,
  • and Roger Foster, M.D.

Abstract

In 1971 we began a randomized trial to compare alternative local and regional treatments of breast cancer, all of which employ breast removal. Life-table estimates were obtained for 1665 women enrolled in the study for a mean of 126 months. There were no significant differences among three groups of patients with clinically negative axillary nodes, with respect to disease-free survival, distant-disease–free survival, or overall survival (about 57 per cent) at 10 years. The patients were treated by radical mastectomy, total ("simple") mastectomy without axillary dissection but with regional irradiation, or total mastectomy without irradiation plus axillary dissection only if nodes were subsequently positive. Similarly, no differences were observed between patients with clinically positive nodes treated by radical mastectomy or by total mastectomy without axillary dissection but with regional irradiation.

Survival at 10 years was about 38 per cent in both groups. Our findings indicate that the location of a breast tumor does not influence the prognosis and that irradiation of internal mammary nodes in patients with inner-quadrant lesions does not improve survival. The data also demonstrate that the results obtained at five years accurately predict the outcome at 10 years. We conclude that the variations of local and regional treatment used in this study are not important in determining survival of patients with breast cancer. (N Engl J Med 1985; 312:674–81.)

Funding and Disclosures

Supported by Public Health Service grants from the National Cancer Institute (NCI-U10-CA-12027 and NCI-U10-CA-34211) and by a grant from the American Cancer Society (ACS-RC-13).

Author Affiliations

From the National Surgical Adjuvant Breast Project Headquarters, Room 914 Scaife Hall, 3550 Terrace St., Pittsburgh, PA 15261, where reprint requests should be addressed to Dr. Bernard Fisher. (See Appendix I for a list of participating institutions and principal investigators.)

Print Subscriber? Activate your online access.